SironRX Therapeutics Receives $500,000 Investment from JumpStart Ventures and Cleveland Clinic

SironRX Therapeutics, Inc., a Cleveland, OH-based company that is developing a topical therapy to enhance healing of and decrease scar formation in wounds, has received a $500,000 investment from JumpStart Ventures and Cleveland Clinic.
The company intends to use the funding, which is part of a larger fundraising round, to begin a Phase II clinical trial evaluating the potential of its lead product, JVS-100, a clinically tested biopharmaceutical that encodes Stromal cell-Derived Factor-1 (SDF-1), which is designed to promote wound repair and prevent scarring in post-surgical wounds.
Pre-clinical studies have demonstrated that there may be broader dermal applications for JVS-100, including treatment of chronic ulcers and burns.
SironRX is a spinoff of the privately-held biotechnology company Juventas Therapeutics, which licensed the drug’s intellectual property from Cleveland Clinic in 2007.
In connection with the funding, Michael Lang, a JumpStart Venture Partner, will now be working with SironRX. CSO of the company is Marc Penn, M.D., Ph.D., Director of the Skirball Cardiovascular Cell Therapy Laboratory at Cleveland Clinic.

Join the discussion